scholarly journals Corrigendum: Racial and Sex Differences in the Response to First-Line Antihypertensive Therapy

2021 ◽  
Vol 7 ◽  
Author(s):  
John S. Clemmer ◽  
W. Andrew Pruett ◽  
Seth T. Lirette
Keyword(s):  
Sex Differences ◽  
Antihypertensive Therapy ◽  
First Line

scholarly journals Beta-Blockers as First-Line Antihypertensive Therapy

2009 ◽  
Vol 54 (13) ◽  
pp. 1162-1164 ◽  
Author(s):  
Carl J. Lavie ◽  
Franz H. Messerli ◽  
Richard V. Milani
Keyword(s):  
Antihypertensive Therapy ◽  
Beta Blockers ◽  
First Line

First-line antihypertensive therapy

The Lancet ◽  
2000 ◽  
Vol 356 (9228) ◽  
pp. 509
Author(s):  
Ross D Feldman ◽  
Norman Campbell ◽  
Pierre Larochelle
Keyword(s):  
Antihypertensive Therapy ◽  
First Line

Sex Differences in Blood Pressure Response to Antihypertensive Therapy in Chinese Patients with Hypertension

2008 ◽  
Vol 42 (12) ◽  
pp. 1772-1781 ◽  
Author(s):  
XiaoHan Fan ◽  
Yunfeng Han ◽  
Kai Sun ◽  
Yibo Wang ◽  
Ying Xin ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Sex Differences ◽  
Antihypertensive Therapy ◽  
Blood Pressure Response ◽  
Pressure Response ◽  
Chinese Patients

First-line antihypertensive therapy

The Lancet ◽  
2000 ◽  
Vol 356 (9228) ◽  
pp. 509
Author(s):  
Franz H Messerli
Keyword(s):  
Antihypertensive Therapy ◽  
First Line

scholarly journals Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first‐line antihypertensive therapy

2021 ◽  
Author(s):  
Revathy Carnagarin ◽  
Janis M. Nolde ◽  
Natalie C. Ward ◽  
Leslie Marisol Lugo‐Gavidia ◽  
Justine Chan ◽  
...  
Keyword(s):  
Antihypertensive Therapy ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
First Line

Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents

2007 ◽  
Vol 25 (7) ◽  
pp. 1499-1505 ◽  
Author(s):  
David F Blackburn ◽  
Darcy A Lamb ◽  
Dean T Eurich ◽  
Jeffrey A Johnson ◽  
Thomas W Wilson ◽  
...  
Keyword(s):  
Observational Study ◽  
Antihypertensive Therapy ◽  
First Line

scholarly journals Antihypertensive therapy in male and female: are there sex differences in choice of drugs?

Kardiologiia ◽  
2019 ◽  
Vol 59 (1S) ◽  
pp. 11-18
Author(s):  
V. N. Larina ◽  
D. A. Orlov
Keyword(s):  
Sex Differences ◽  
Antihypertensive Therapy ◽  
Protective Action ◽  
Male And Female ◽  
Treatment Of Hypertension

Tis review presents data on prevalence, control, and effectiveness of treatment of hypertension in male and female. Te features of protective action and manifestations of undesirable effects of antihypertensive therapy in male and female, as well as situations influencing the choice of a drug depending on sex are discussed.

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4029-4029
Author(s):  
Anna Dorothea Wagner ◽  
Manel Rakez ◽  
Benoist Chibaudel ◽  
Richard Adams ◽  
John Raymond Zalcberg ◽  
...  
Keyword(s):  
Sex Differences ◽  
Performance Status ◽  
Single Agent ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Tumor Characteristics ◽  
First Line ◽  
Braf Mutations ◽  
Cox Models ◽  
The Impact

4029 Background: The clearance of 5-FU differs significantly between men (M) and women (W). Adjuvant chemotherapy (CT) for CRC has a higher toxicity in W. The impact of sex on efficacy and toxicity in first-line trials of metastatic CRC (mCRC) is unknown. Methods: We analyzed patient (pt) and tumor characteristics, toxicities (nausea (AE1), vomiting (AE2), diarrhea, neutropenia (AE3)) and efficacy (overall survival (OS), progression-free survival (PFS)) according to sex in the following treatment groups: A: CT alone, B: CT + bevacizumab, C: CT + EGFR-antibodies, with subgroup analyses in the CT alone group for single-agent, doublets and triplets, as well as irinotecan- and oxaliplatin-based regimens. Pts from trials with treatments still used today and all relevant data available were eligible. OS and PFS were assessed using Kaplan-Meier and Cox models adjusted for primary tumor location and performance status (PS). Results: We included 28 trials with 18.399 pts (11.352 M and 7.047 W). W were younger (61 vs. 63 years), had more often a PS of 1 (49 vs 45%), BRAF mutations (10 vs. 7%), right-sided tumors (42 vs. 35%) and less often rectal tumors (26 vs. 32%). Significant differences in toxicity are reported in table. Rates of diarrhea were similar. There was no sex disparity in OS in the predefined subgroups except for pts receiving triplets where OS was better in M (HRadj=1.39 (1.05 - 1.85)). Median (interquartile range) OS in months for M and W was 16.7 (9.2-27.4) and 16.2 (8.9-27.2) in group 1, 21.9 (12.7-37.5) and 22.3 (12.9 – 39.0) in group 2, and 26.8 (14.6-45.3) and 24.8 (12.3-49.2) in group 3. HRsadj (W vs M) (95% CI), p values for OS were 1.02 (0.96-1.09), .557, 0.92 (0.83-1.03), .142, 0.99 (0.85-1.14), .866. Conclusions: M and W with mCRC differ significantly regarding patient and tumor characteristics. The significant higher toxicity in W does not translate in a higher treatment efficacy. Apart from known sex differences in pharmacokinetics of 5-FU, differences in pharmacodynamics must be postulated. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document